Functional Neurological Disorder (FND) involves neurological symptoms arising from brain network changes rather than structural damage, often described as a “software” issue rather than a “hardware” problem. Symptoms…
Pompe disease is a progressive, life-threatening genetic neuromuscular disorder. Late-onset Pompe disease (LOPD), affecting individuals over one year old, leads to trunk and proximal muscle weakness, often impacting…
At the American Academy of Neurology meeting, researchers gave final results of the phase III PRECISE trial of glatiramer acetate (Copaxone), which delayed the onset of clinically confirmed…
The American College of Physicians and the American Academy of Family Physicians issued clinical practice guidelines about the pharmacologic treatment of dementia. From our partners at VerusMed verusmed.com…
In BMC Neurology it is reported that pesticide exposure may boost the risk of developing Parkinson’s disease over and above genetic factors. References and Resources Hancock D, Martin…
An open randomized trial showed that for a first episode of schizophrenia, four second-generation antipsychotics were no more effective than haloperidol, but they did have lower discontinuation rates.…
A blood test for mood disorders that enables better diagnosis and treatment may be feasible by extracting RNA to measure the expression of various genes identified as biomarkers…
A new study indicates that a single course of rituximab reduces inflammatory brain lesions and clinical relapses for as long as 48 weeks in patients with relapsing-remitting multiple…
This video discusses a cross-sectional study examining age and gender-specific z-score total bone mineral density (z-BMD) in 108 ambulatory children with epilepsy between 6 and 18 years of…
James P. Moises, MD, Assistant Clinical Professor of Surgery, Department of Emergency Medicine, Clerkship Director of Emergency Medicine, Tulane University Hospital and Clinic, discusses the management for closed…
Impax Laboratories Inc. received a nonapprovable letter from the FDA regarding its New Drug Application and subsequent submissions for carbidopa/levodopa extended-release tablets. The FDA’s decision was primarily based…
The results of a phase II, multicenter trial that included 25 adult patients with newly diagnosed disease reported that patients maintained a complete response to treatment with high-dose…
